Cabaletta Bio Inc (CABA) Stock: Assessing the Risk and Reward

4h ago, source: newsheater

In summary, Cabaletta Bio Inc (CABA) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note ...

CABA Cabaletta Bio, Inc.

5d ago, source: Seeking Alpha

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.

Several Factors Led to the Outperformance of Cabaletta Bio (CABA) in Q4

1mon ago, source: InvestingChannel on MSN

Alger Small Cap Growth Fund featured stocks like Cabaletta Bio, Inc. (NASDAQ:CABA) in its Q4 2023 investor letter.

Cabaletta Bio Receives FDA Orphan Drug Designation for Innovative Autoimmune Disease Therapy

1mon ago, source: MyChesCo on MSN

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced that the U.S. Food and Drug Administration (FDA) has awarded ...

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

1mon ago, source: Business Insider

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with ...

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis

1mon ago, source: Business Insider

PHILADELPHIA, March 20, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell ...

Cabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash Runway

1mon ago, source: Yahoo Finance

Warning! GuruFocus has detected 2 Warning Sign with CABA. On March 21, 2024, Cabaletta Bio Inc (NASDAQ:CABA) released its 8-K filing, detailing the fourth quarter and full year financial results ...

Cabaletta Bio Inc.

28d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Cabaletta Bio Inc (CABA)

2mon ago, source: Investing

On Thursday, Stifel, a financial services firm, raised its price target on shares of Cabaletta Bio Inc . (NASDAQ:CABA) to $32 from $31 while maintaining a Buy rating. The ...